The general term flavonoids is often used to categorize a family of natural compounds that are highly abundant in all higher plants, and which in recent years have attracted scientific interest as therapeutics. Lutein is a xanthophyll and one of 600 known naturally occurring carotenoids. It is found in green vegetables such as spinach and kale, and has been demonstrated to exert anti-inflammatory activities. However, its anti-allergic effect in the Th1/Th2 immune response is poorly understood. In this study, we attempt to determine whether lutein regulates inflammatory mediators in an ovalbumin (OVA)-induced murine asthma model. To address this, mice were sensitized and challenged with OVA, and then treated with lutein before the last OVA challenge. Administration of lutein significantly suppressed the OVA-induced airway hyper-responsiveness. It also resulted in a significant alleviation of the infiltration of inflammatory cells into the bronchoalveolar lavage. Additionally, lutein attenuated the increased expression of Th2 responses in OVA-challenged mice. These results demonstrate that lutein is a potent inhibitor that reduces Th2 immune responses. Furthermore, they show that the immunopharmacological function is mediated by a pathway that involves and is regulated by Th2 immune response.
Introduction
Asthma is a chronic inflammatory lung disease that is characterized by airway hyperresponsiveness (AHR) to allergens, airway edema and increased mucus secretion [4, 9] . Inflammatory lung disease usually results from the infiltration of eosinophils, neutrophils, macrophages and lymphocytes into the bronchial lumen and lung tissues [20, 21] . Recruitment of these inflammatory cells from blood to the site of inflammation is regarded as a critical event in the development and persistence of airway inflammation [8, 22] .
In particular, it has been reported that eosinophil infiltration into the asthmatic lung leads to degranulation and release of eosinophil peroxidase (EPO), resulting in airway epithelial damage and the development of AHR [24, 26] .
Previous studies have shown that eosinophils infiltrating into the lung preferentially stimulate T-helper type 2 (Th2) cell responses by presenting antigens [1, 15, 16] . Therefore, Th2 cells are dominant in the airways [2] and Th2 cytokines, such as IL-4, IL-5 and IL-13, play a pivotal role in the pathophysi-ology of asthma [10, 17, 18] .
The balance between Th1 and Th2 cells is tuned by interactions between transcription factors. One of the major transcription factors regulating the expression of Th2 cytokine is STAT6 [5, 7, 25] . STATs have been shown to be important in the regulation of cytokines and growth factor-inducible transcription factors in immune response [19, 23] . Recent studies using STAT6-deficient mice the demonstrated that phosphorylation and nuclear translocation of STAT6 are critical for the development of Th2 cell differentiation and airway responses. The significant role of STAT6 in airway inflammation was further supported by findings in asthmatic patients who showed increased levels of STAT6 expression in their lungs [14] . IL-4, a prototype Th2 cytokine, enhances Th2 cell development through STAT6, which activates GATA3 genes [6] . GATA3, a downstream transcriptional factor of STAT6, plays a key role in Th2 cell development by promoting Th2 cytokine expression by binding to a variety of regulatory regions of Th2 cytokines [7] . On the other hand, IL-12 drives Th1 cell differentiation through the activation of STAT4 and T-box expressed in T cells (T-bet), Th1 transcription factors, which up-regulates IFN-γ and down-regulates IL-4 and IL-5 production [12] . Lutein plays a role in various pharmacological responses, including anti-inflammatory, anticarcinogenic and free radical-scavenging activities, in a variety of in vitro systems [11] . In this study, we attempted to characterize the effects of lutein in a murine model of asthma and to determine whether lutein treatment would inhibit asthmatic syndrome and suppress OVA-induced gene expressions of STAT-6 and GATA-3.
Materials and methods

Animals and experimental protocol
Female BALB/c mice, 6 weeks of age and free of murine-specific pathogens, were obtained from Charles River Laboratories (Yokohama, Japan). All experimental animals used in this study were maintained under a protocol ap- Mice were challenged via the airway with OVA (3% OVA) for 30 minutes every day from day 20 to day 22. BAL fluid was obtained at 24 hours after the last challenge. For the extraction of lavage, mice (10 mice in each group) were killed with an overdose of ether. The chest cavity was exposed for expansion, after which the trachea was carefully intubated and a catheter was secured with ligatures.
Administration of lutein
We injected 200 μl of either 1 or 10 mg/kg lutein (Sigma-Aldrich) i.p. into each mouse every day from day 16 to day 19.
Total cell counts
The total number of cells was counted with a hemocytometer. Smears of BAL cells prepared with a cytospin II (Shandon, Runcorn, UK) were stained with Diff-Quik solution (Dade Diagnostics of P.R. Inc, Aguada, PR) for differential cell counting. Two independent, blinded investigators counted the cells using a microscope.
Approximately 200 cells were counted in each of the 4 random locations.
Histopathology
The mice were sacrificed and their lungs were removed 48 hours after the last challenge. Prior to removal, the lungs and trachea were intratracheally filled with 4% paraformaldehyde, a fixative, using a ligature around the trachea.
The specimens were dehydrated and embedded in paraffin. 
Determination of airway responsiveness to methacholine
Results
Lutein reduces the number of inflammatory cells in BAL fluid
Inflammatory lung disease including asthma usually results from the infiltration of eosinophils, neutrophils, macrophages and lymphocytes into the bronchial lumen and lung tissues. The total numbers of cells, eosinophils, lymphocytes and macrophages in BAL fluid were more significantly increased 24 hours after OVA inhalation than after saline inhalation. The increased number of eosinophils was significantly reduced by the administration of lutein (Fig. 1 ).
Lutein reduces the levels of Th2 cytokines in the lung tissues of mice sensitized to and challenged with OVA The Th2-type cytokines IL-4, IL-5, and IL-13, produced by activated CD4+ T cell play an important role in the pathogenesis of asthma by controlling the key process of immunoglobulin (IgE) production, growth of mast cells and the differentiation and activation of mast cells and by the administration of lutein (Fig. 3) . The above-mentioned pathophysiological phenomena were dramatically decreased by the administration of lutein, and these results suggest that lutein inhibits OVA-induced inflammation in the lungs. Lutein decreases STAT6 and GATA3 expression in the lung tissues of mice sensitized to and challenged with OVA Western blot analysis revealed that the expressions of STAT6 and GATA3 proteins in lung tissues was more significantly increased 24 hours after OVA inhalation than after saline inhalation (Fig. 4) . The increased protein expressions of STAT6 and GATA3 were reduced when lutein was administered compared to control protein expression.
Lutein decreases airway hyperresponsiveness
Airway responsiveness was assessed as the percentage increase in the basis of Penh in response to increasing doses of methacholine. In OVA-sensitized and OVA-challenged mice, the dose-response curve of percentage Penh was shifted to the left compared to that of the control mice. In addition, methacholine administration (2.5 mg/ml to 50 mg/ml) significantly increased the percentage Penh in OVA-sensitized and OVA-challenged mice compared to the controls.
OVA-sensitized and OVA-challenged mice treated with lutein showed a dose-response curve of percentage Penh that was shifted to the right compared to that in untreated mice, and this shift was dose-dependent ( Fig. 5) . These data indicate that lutein treatment reduces OVA-induced airway hyperresponsiveness. Fig. 5 . The effect of lutein on airway responsiveness in OVA-sensitized and OVA-challenged mice. Airway responsiveness was measured 24 hours after the last challenge in the mice which received the control treatment (CON), OVA plus lutein at 1 mg/kg/day (OVA + Lut 1 mg), OVA plus lutein at 10 mg/kg/day (OVA + Lut 10 mg) and OVA (OVA). Airway responsiveness to aerosolized methacholine was measured in conscious unrestrained mice. The mice were placed in the main chamber, nebulized with PBS, and then administered increasing doses of methacholine (2.5 to 50 mg/ml) for 3 minutes for each nebulization. Readings of breathing parameters were taken for 3 minutes after each nebulization while Penh values were determined. The data from the 5 independent experiments are expressed as the mean±SEM. Statistical significance: ***p<0.001.
Lutein decreases IgE levels in serum
Because Th2 cytokines promote airway inflammation in asthma through increased IgE levels, we investigated the expression of IgE associated with Th2 response in airway inflammation. We measured how lutein modulates serum IgE levels in OVA-challenged mice. As predicted, we observed that IgE expression was remarkably increased by OVA challenge. However, administration of lutein significantly reduced the level of IgE in serum ( Fig. 6) . These data indicate that lutein modulates IgE levels associated with the Th2 response in an OVA-induced asthma model.
Lutein inhibits ROS generation in bronchoalveolar lavage fluid
We indirectly measured tissue injury status via ROS levels in BALF. The ROS levels were higher in OVA-sensitized and OVA-challenged mice. However, administration of lutein significantly reduced the ROS level in BALF (Fig. 7) . This result indicates that lutein impaired tissue injury status through diminishment of ROS generation. 
Discussion
This study is the first to provide experimental evidence demonstrating that lutein inhibits OVA-induced airway inflammation in a murine model of asthma. OVA-induced asthma has been recognized as a disease that results from chronic airway inflammation characteristically associated with the infiltration of lymphocytes, eosinophils and neutrophils into the bronchial lumen [1] . Lutein markedly inhibited asthmatic reactions, such as leukocytic recruitment into the airway and lung inflammation.
It has been well recognized that in chronic asthma, Th2 lymphocytes infiltrate into the lungs and produce inflammatory cytokines, including IL-4, IL-5 and IL-13 [27] .
These cytokines may induce the expression of inflammatory molecules in both the endothelial cells of bronchial circulation and the epithelial cells in the airway and may also promote recruitment of lymphocytes and eosinophils [13] . Lutein reduced expressions of STAT-6 and GATA-3 in OVA-sensitized and OVA-challenged mice (Fig. 4) . This suggested that lutein treatment is a novel, selective way to simultaneously suppress Th2 immune responses in asthmatic reactions in vivo. We also examined Th1/Th2 cytokine production in BAL fluid cells and found that lutein reduced the increased levels of IL-4, a Th2 cytokine, in OVA-sensitized and OVA-challenged mice.
IL-4, induces isotype switching in B cells from IgG to
In summary, our results strongly suggest that lutein may reduce allergic airway inflammation through an alteration of the Th1/Th2 balance by suppression of STAT6 and GATA3. It is believed that administration of lutein might be a new therapeutic approach to allergic airway diseases.
